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Accepted 20 July 2012AbstractObjective: This study aims to determine the effects of curcumin and demethoxycurcumin on the internal ribosome entry site of the amyloid-
b precursor protein (APP) and tau protein through a bi-cistronic reporter assay for screening of anti-Alzheimer’s disease agents.
Materials and Methods: A bi-cistronic assay was performed wherein the expression of the first cistron, a b-galactosidase gene under the control
of a cytomegalovirus promoter, represents the canonical cap-dependent mechanism of translation initiation; while the second cistron involves the
utilization of the APP or the tau IRES elements to drive the expression of secreted alkaline phosphatase (SEAP) under a cap-independent
mechanism. Bioactive natural products reported to have therapeutic potential for AD such as curcumin and demethoxycurcumin were screened
in an murine neuroblastoma (N2A) cell model. Western blot analyses for the expression of APP C-terminal protein, human tau-1, and phos-
phorylated tau at Serine 262 (p262) and Serine 396 (pS396) were done after treatment of N2A cells with the test compounds.
Results: The bi-cistronic reporter assay revealed that curcumin was more effective than demethoxycurcumin, a structural analog of curcumin, in
inhibiting both APP and tau IRES-dependent translation initiation. This result was further confirmed by Western blot analysis for the expression
of APP C-terminal protein, human tau-1, pS262 and pS396 suggesting that curcumin may play a role in AD pathology alleviation through the
inhibition of the APP and tau IRES-mediated translation mechanism. On the other hand, demethoxycurcumin was observed to inhibit the
phosphorylation of both tau pS262 and pS396.
Conclusion: A novel assay system using the bi-cistronic reporter constructs for the identification of compounds with activity against the
translation directed by APP and tau IRES was developed. The results provide novel suggestive insights for the potential use of the mentioned
compounds as prophylactic and therapeutic anti-AD agents.
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Demographic aging is a global process that denotes the
successes of improved healthcare over the past years. Today,
human life expectancy is significantly longer, resulting in
a much greater proportion of elderly people. Nevertheless,
aging imposes some challenges. It has been well documented
that in parallel to aging there is also an increase in cases of
Alzheimer’s disease (AD) and other dementias in the senile
but modern society [1]. Cardinal features of AD pathology
include synaptic and neuronal loss, astrocytosis, intraneuronal
inclusions of the hyperphosphorylated tau protein in neurofi-
brillary tangles, and the extracellular deposition of amyloid-
b protein in senile plaques. Scientists around the globe have
been searching for decades to treat and put an end to the
pathological symptoms of AD that deprives our elderly society
their intellect, but scientists have met limited success [2].
In spite of the Herculean efforts, only four FDA-approved
drugs are currently commercially available in the USA to
treat AD pathology [3]. Recent studies demonstrated that the
amyloid precursor protein (APP) mRNA may be translated
through an internal ribosome entry site (IRES) wherein APP
mRNA was found to be one of several mRNAs that may
remain associated with polyribosomes during mitosis, when
cap-dependent translation initiation is greatly diminished [4].
However, it has also been reported that the 50 leader in the
human tau mRNA contains an IRES and that IRES-dependent
translation plays a significant role in the generation of tau
protein [5]. Thus, the inhibition of APP and tau expression
provides a novel strategy in the continuous battle against
neurodegenerative AD. The use of IRES elements to promote
internal initiation of translation of RNA has made possible the
expression of two or more proteins from polycistronic units in
eukaryotic cells. A number of reviews have presented the
efficiency of using the bi-cistronic vectors wherein the first
gene is translated in a cap-dependent manner while the
translation of the second gene is driven by the IRES-dependent
mechanism [6,7]. We have developed some recombinant bi-
cistronic baculovirus constructs to express pharmaceutically
and biotechnologically important recombinant proteins such as
interferon-g (IFN-g) [8] and Chikungunya virus (ChiKV) 26S
[9] and for the screening of drugs or compounds for translation
initiation regulation [10].
Plants are the most precise laboratories ever created
because they can synthesize metabolites with the most abso-
lute configuration. Many of our available medicines in the
market are of plant origin [11]. The drugs available for AD
mainly target cholinergic functions associated with the said
disease, leaving a vast majority of other potential AD targets
nearly unexploited by treatment. Therefore, there is an urgent
need for developing drugs based on multiple pathomechan-
isms of AD. Thus, anti-AD drug design aiming to inhibit the
IRES-dependent mechanism of translation initiation was put
forward to open new avenues for therapeutic modalities with
low cellular toxicity [12,13]. The enormous diversity of
functions in natural compounds extracted and isolated from
either plant or marine sources may provide a new generationof drugs for AD therapy and management [14,15]. Plant-
derived drugs are popular because the public believes that
herbs are naturally safer than synthetic drugs. These beliefs
may account for the sudden increase in herbal use during
recent decades [16].
Curcumin and demethoxycurcumin were selected in this
study from a long list of compounds of plant origin to be tested
for their ability to inhibit the cap-independent translation
mechanism based on the inhibition of APP and tau IRES
activities. Curcumin is a bright yellowpowder that is also known
as deferuloylmethane, natural yellow 3, and (1E,6E )-1,7-bis(4-
hydroxy-3-methoxyphenyl) hepta-1,6-diene-3,5-dione. This
substance is isolated from the plantCurcuma longa, or turmeric,
commonly used for culinary purposes. This substance possesses
several functional groups wherein the planar aromatic ring
systems are attached to a,b-unsaturated carbonyl groups. The
diketones generate stable enols that could be easily deproto-
nated to form enolates. The a,b-unsaturated group can undergo
nucleophilic addition and the Michael reaction. Curcumin has
been shown to possess a wide range of pharmacological activ-
ities including anti-inflammatory [17,18], antioxidant [19],
anticancer [20], wound healing [21], and antimicrobial effects.
Demethoxycurcumin, a structural analog of curcumin having
one fewer methoxy group, was also isolated from C longa. It is
an orange powder with a formula weight of 338.35 g/mol. Its
IUPAC name is (1E,6E )-1-(4-hydroxy-3-methoxyphenyl)-7-
(4-hydroxyphenyl)hepta-1,6-diene-3,5-dione, and it is also
referred to as desmethoxycurcumin, monodemethoxycurcumin,
and para-hydroxycurcumin. Demethoxycurcumin shares bio-
logical activities with curcumin. Along with curcumin and
bisdemethoxycurcumin, the compound demethoxycurcumin
has also shown its antioxidant ability based on the reduction of
Mo (VI) to Mo (V). The antioxidant capacity of the curcumi-
noids tested were found to decrease in the order:
curcumin > demethoxycurcumin > bisdemethoxycurcumin
[22]. This study utilizes a bi-cistronic construct containing the
specified IRES flanked by b-galactosidase and secreted alkaline
phosphatase (SEAP) genes; the expression of the b-galactosi-
dase gene is controlled by the cytomegalovirus (CMV)while the
SEAP expression is under the control of the IRES element.Materials and methodsChemicals and reagentsAll chemicals and reagents used in this study are of reagent
grade. Materials used for cell culture were obtained from
Invitrogen, Carlsbad, CA. Fetal calf serum was purchased
from Biological Industries, Taipei, TW. Curcumin (C1386,
CAS No. 458-37-7) and Demethoxycurcumin (D7696, CAS
No. 22608-11-3) were obtained from Sigma-Aldrich, St.
Louis, MO. The restriction enzymes used were from Takara,
Shiga, JP. Luria broth medium and Luria agar medium were
from Lab M Ltd., Lancashire, UK and Alpha Biosciences,
Baltimore, MD, respectively. Agarose and bis-acrylamide/
acrylamide (29:1, w/v) solution were from AMRESCO,
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and each experiment was repeated three times.Culturing of cells, plasmid construct, retransformation,
and transfection into N2A cellsThe cells,murine neuroblastoma (N2A),were cultured in aT-
75 flask with 10 mL of culture medium supplemented with 10%
fetal calf serum. The cells were allowed to settle to the bottom of
the flask during incubation at 37C in a humidified incubator.
After 5 hours, the medium was replenished. The cells were
allowed to proliferate to confluency at 37C in a humidified CO2
incubator. Cells were passaged every 2e3 days to be used for
successive assays. Previously prepared plasmid DNAs were
used in this study. The plasmid pUC57 (NCBI No. NM016835)
containing the tau IRES gene was synthesized by PROTECH
Technology Company, Taiwan. The 240 bp tau IRES was cut
from pUC57 by enzymatic digestion with NotI and cloned into
the NotI treated plasmid-pGS-EMCV to replace the EMCV
IRES fragment. A similar procedure was done for the insertion
of the APP IRES gene into the other pUC57. The APP and the
tau IRES contained in pUC57 (NCBI No. NM00084) was
amplified by PCR using two pairs of primers: (1Forward:
ATTGCGGCCGCAGTTTCCTCGGCAGCGGTAGGCGAGA
GCACGCGGAGGAGCGTGCGC; 2Reverse: TCTGCCCGC
GCCGCCACCGCCGCCGTCTCCCGGGGCCCCCGCGCA
CGCTCCTCCGCGT; 3Forward: TGGCGGCGCGGGCAGA
GCAAGGACGCGGCGGATCCCADTCGCACAGCAGCGC
ACTC; 4Reverse: TATGCGGCCGCCGCGACCCTGCGCGG
GGCACCGAGTGCGCTGCTGTGCGA). The restriction sites
in NotI are underlined. The plasmids were generated as pGS-
APP and pGS-Tau, respectively. In each plasmid, the IRES
element from the genes of either APP or tau was flanked by the
reporter genes b-galactosidase and SEAP, respectively.
Before transfection, themammalian cells (w7e8 104 cells/
mL)were seeded on a 24-well plate in serum-freeMEM forN2A
cells. The cellswere allowed to grow and to proliferate up to 90%
confluency and the mediumwas replenished. The plasmids were
transfected via liposomes using either TurboFect (Fermentas
Life Science, Burlington, ON) or Lipofectamine (Invitrogen)
following manufacturers’ protocols. Briefly, the plasmid DNA
and the liposome (1:2) were mixed in a centrifuge tube. The
mixture was allowed to form a complex for 5 minutes at room
temperature. The DNAeliposome complex was added to the
cells dropwise with gentle mixing by rocking the plate back and
forth. The total volume of the medium and DNAeliposome
complex was 400 mL. Themixturewas then centrifuged at 600
g for 10 minutes to allow the DNAeliposome complex to settle.
The cells were incubated at 37C, 95% air/5% CO2. After 18
hours of incubation, the cells were treated with various concen-
trations of each compound used in this study.MTT cytotoxicity assayThe cytotoxic effect of each compound on N2A cells tested
in this study was determined using the 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Thisexperiment was carried out in parallel to transfection studies.
N2A cells at a density of 104 cells per well, were treated with
desired concentrations of the selected compounds for anti-AD
and anti-EV71 screening for 24 hours. Light was avoided
throughout the course of the experiment. About 30 mL of MTT
solution was added to the 100 mL mammalian cell culture in
a 96-well plate. The MTT-treated cells were incubated at 37C
in a humidified CO2 incubator for 1 hour allowing the devel-
opment of purple formazan crystals. Afterward, 100 mL of
dimethylsulfoxide (DMSO) was added to dissolve the formed
formazan crystals. Absorbance was read by a microtiter UV
spectrophotometer at a wavelength of 562 nm. Percent
survival was calculated using the formula from the paper of
Raval et al [23]:
% Survival¼ AbsorbanceTREATEDAbsorbanceCONTROL
AbsorbanceCONTROLAbsorbanceBLANKScreening of compounds for IRES activity inhibitionThe cells were treated with various concentrations (1 mM,
5 mM, 10 mM, 20 mM, and 40 mM) of curcumin or deme-
thoxycurcumin. After 24 hours treatment, the cell medium was
aspirated and kept frozen at e20C for the SEAP assay. The
remaining adherent cells were lysed using 100 mL of Cyto-
buster protein extraction reagent, centrifugation at 15,800  g
for 10 minutes at 4C followed, and the supernatant was kept
at e20C for the succeeding b-galactosidase assay. Mem-
antine was used as a positive control [24]. The SEAP and b-
galactosidase assays were conducted as previously described
[10,25].Western blot analysisIn another independent experiment, the effect of selected
compounds on the expression of APP, C-terminal tau proteins
phosphorylated at Serine 262 (Tau pS262) and Serine 396 (Tau
pS396), and total human tau protein was investigated. Prior to
western blot analysis, N2A cells (7e8  104 cells/well) were
seeded onto a 24-well plate and were treated with various
concentrations of the selected natural products for 24 hours at
37C, 95% air/5% CO2. Then, the culture medium was aspi-
rated and was discarded. The adherent cells were then lysed
with 100 mL of Cytobuster protein extraction reagent, centri-
fugation followed at 15,800  g for 10 minutes at 4C, and the
supernatant was then kept at e80C until used. Total protein
concentration determination for each sample was determined
using a bicinchoninic acid assay. Proteins were resolved by
denaturing and reducing 8e10% sodium dodecylsulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) at
a constant 80 V for 30 minutes. The voltage was changed to
110 V and proteins were resolved for 2 hours at room
temperature. After SDS-PAGE, the proteins were electro-
transferred onto a polyvinylidene fluoride (PVDF) membrane
(0.45 mm porosity, Immobilon-P, Millipore) at 80 V for 2.5
hours. Immediately after transfer, the membrane was stained
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Fig. 1. Structures of curcumin and demethoxycurcumin.
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proteins to the PVDF membrane. Then, the membrane was
washed repeatedly with 1 Tris buffered saline to remove the
stain. The membrane was then blocked with 5% non-fat milk
in Tris buffered saline-0.1% Tween 20 (TBS-T) buffer over-
night at 4C with shaking at 150 rpm. Washing was done three
times with TBS-T buffer for 30 minutes (10 minutes/wash,
150 rpm). The individual blocked membrane was then incu-
bated with the respective primary polyclonal antibody at the
desired dilution in TBS namely rabbit anti-APP-C-terminal
(1:1,000, Cat. No. A8717, Sigma), rabbit anti-TaupS262
(1:2,500, Sigma), rabbit anti-TaupS396 (1:2,500, Sigma), and
rabbit anti-human tau (1:1,500, Sigma). Incubation with
primary antibody was performed overnight at 4C with
shaking at 150 rpm. The unbound primary antibodies were
removed by washing thrice with TBS-T at room temperature,
150 rpm (10 minutes/wash). Then, the membrane was indi-
vidually incubated with the anti-rabbit secondary antibody
labeled with horseradish peroxidase (1:3,000; Cat. No. 7074;
Cell Signaling Technology, Danvers, MA) at 4C with shaking
at 150 rpm for 4 hours. Three-times washing at 150 rpm, 10
minutes per wash, immediately followed to remove the
unbound antibodies. Beta-actin (1:10,000, Sigma) was used as
an internal control. Proteins were detected using an enhanced
chemiluminescence kit (VistaGlow Chemiluminescent
Substrate, Cat. No. VG01-500; Visual Protein Biotechnology
Corporation, Taipei, TW) following the supplier’s protocols.
Bands were visualized by Fuji camera along with Fuji Image
LAS-3000 software and bands were quantified using the
ImageJ Analysis software and were presented as relative area
corresponding to the target protein expression. Data presented
are results from three independent experiments.
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Fig. 2. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
assay for curcumin and demethoxycurcumin. The neuroblastoma (N2A) cells
(w104 cells/well) were seeded on a 96-well plate and were subsequently
treated with different concentrations of (A) curcumin and (B) demethox-
ycurcumin. At 24 h after treatment with these compounds, 30 mL of thiazolyl
blue tetrazolium bromide (5 mg/mL) was added. The purple formazan crystals
formed were dissolved in dimethylsulfoxide (DMSO), and the absorbance at
562 nm was measured on a spectrophotometer.The MTT assay is a generally accepted method to deter-
mine cell viability. MTT, a yellow solution, is reduced by the
mitochondrial dehydrogenases in living cells to a blue-
magenta colored formazan precipitate. The absorption of
dissolved formazan in the visible region correlates with the
number of intact alive cells. Certain compounds may cause
damage to cells when added to the culture medium, thereby
affecting the viability of the cells [26]. Cytotoxicity evaluation
is of paramount importance prior to screening of compounds
for anti-AD so as to improve the selection process of potential
drugs/plant extracts for the treatment of AD. Thus, curcumin
and demethoxycurcumin (Fig. 1) were evaluated for their
cytotoxic effects on N2A cells. The results presented in this
section were obtained from the MTT assay performed in
parallel with transfection studies and western blot analysis. It
can be observed in Fig. 2 that the compounds tested against
murine N2A cells are relatively nontoxic at the concentrations
used. It is also worth noting that demethoxycurcumin exhibits
a dose-dependent increase in the N2A cells’ viability indi-
cating that it (Fig. 2B) is not toxic within the concentrationtested. Demethoxycurcumin even promoted the proliferation
of N2A cells 24 hours posttreatment as manifested by a 6%
increase in the viability as compared to the untreated cells.
However, curcumin showed a marginal toxicity resulting to
558 O.B. Villaflores et al. / Taiwanese Journal of Obstetrics & Gynecology 51 (2012) 554e564about 60% survival in N2A cells at a concentration of 40 mM,
(Fig. 2A). It was also noted that curcumin did not cause any
toxic effect at concentrations <10 mM.
The expression of APP and tau proteins has been demon-
strated in a number of reported studies to be mediated by the
IRES, an atypical translational initiation mechanism, aside
from the conventional cap-dependent translation initiation
[4,5]. It has been assumed that it could be possible to identify
compounds that may be able to distinguish between cap-
dependent translation and cap-independent IRES-mediated
translation. In the facilitation of compound screening,
bi-cistronic reporter constructs were developed containing
a b-galactosidase gene and a SEAP reporter gene. In each
bi-cistronic expression vector, the b-galactosidase and SEAP
reporter genes are under the transcriptional control of the
human cytomegalovirus major intermediate early promoter/
enhancer sequence (CMV promoter). Directly after transcrip-
tion, the b-galactosidase gene is translated by a cap-dependent
mechanism, while SEAP expression is directed by either APP
(Fig. 3A) or tau IRES (Fig. 3B). This model can possibly
recognize compounds that can stall SEAP expression repre-
senting the cap-independent translation without affecting
b-galactosidase activity that represents cap-dependent trans-
lation initiation in transfected cells.Curcumin but not demethoxycurcumin affects APP-
IRES-mediated translation initiation in murine
neuroblastoma cellsEstablished through various studies, turmeric, a popular
spice, is useful in the therapeutic management of AD [27].
Here, curcumin and its structural analogue, demethox-
ycurcumin were tested for their ability to inhibit the APP-
IRES-directed translation initiation in a transfected mouse
neuroblastoma cell line. In Fig. 4, curcumin was able to cause
a minimal effect on the SEAP activity at concentrations of
1e20 mM (up to 20% inhibition of SEAP activity). At these
concentrations, the b-galactosidase activity was not signifi-
cantly affected by the treatment of N2A cells with curcumin.
This implicates that curcumin was able to inhibit the APP-
IRES activity without affecting the cap-dependent mecha-
nism. Treating the transfected cells with 40 mM curcumin
resulted in a more pronounced inhibition of SEAP, but the b-Fig. 3. DNA plasmid constructs. These constructs contain the elements from (A) am
The plasmids use the cytomegalovirus (CMV) promoter to drive the bi-cistronic mgalactosidase activity was reduced to almost 60% and if this
result is correlated with the result of the MTT assay, it can be
deduced that curcumin is relatively nontoxic at a concentration
<10 mM. In contrast, demethoxycurcumin did not inhibit the
APP-IRES-dependent translation initiation in transfected
mouse neuroblastoma cells as shown in Fig. 5. Within the
concentration range used (1e40 mM) demethoxycurcumin
promoted the activity of SEAP; therefore, there is an observed
promotion of the APP-IRES-mediated translation initiation.
The b-galactosidase assay showed that increasing the amount
of demethoxycurcumin from 1 mM to 40 mM in the culture
medium favors the expression of b-galactosidase protein
within the cell, thereby increasing the occurrence of cap-
dependent translation initiation within the N2A cells. Simi-
larly, the result of the MTT assay for demethoxycurcumin is
consistent with the b-galactosidase assay.Curcumin is more active in attenuating APP expression
than demethoxycurcuminBased on the results presented in the previous section,
curcumin was able to cause an effect on the APP-IRES-
mediated translation initiation while demethoxycurcumin
seemed to favor the activity of APP-IRES. It was hypothesized
that these compounds would have a similar pattern of effect on
the expression of APP in the mouse neuroblastoma cells. The
N2A cells were treated with 1 mM, 5 mM, 10 mM, 20 mM, and
40 mM of either curcumin or demethoxycurcumin for 24
hours. Subsequently, the cell lysates were subjected to western
blot analysis to investigate the effect of the said compound on
the expression of particularly the C-terminal of human APP695
(676e695). APPs are members of a large family of trans-
membrane glycoproteins widely distributed in many tissues.
APP has three major isoforms: APP695, APP751, and APP770.
Both APP751 and APP770 contain a 56 amino acid domain.
APP695 is preferentially expressed in the central nervous
system while the other two are more abundant in the periph-
eral nervous system [28]. APP is thought to be internalized
and degraded by an endosomalelysosomal pathway to yield
amyloidogenic peptides that are cytotoxic and cause neuronal
damage and degeneration. As quantified using the ImageJ
software, the results of the western blot analysis were in
agreement with the data obtained from the SEAP reporteryloid precursor protein (APP) and (B) Tau internal ribosome entry site (IRES).
RNA transcription in transfected mammalian cells.
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Fig. 5. Effects of demethoxycurcumin on the cap-dependent and amyloid
precursor protein-internal ribosome entry site (APP-IRES)-mediated trans-
lation initiation in neuroblastoma cells. About 7e8  104 N2A cells were
seeded on a 24-well plate. A DNA plasmid containing IRES elements of the
50UTR amyloid precursor protein (pGS-APP) was transfected using Turbofect
reagent with centrifugation at 600 g at 26C for 10 min. Cells were allowed
to multiply and were treated with various concentrations of demethox-
ycurcumin (1 mM, 5 mM, 10 mM, 20 mM, and 40 mM) for 24 h. Then the cell
medium was aspirated and subjected to a secreted alkaline phosphatase
(SEAP) activity assay while the adherent cells were lysed by Cytobuster and
lysates were subjected to a b-galactosidase assay.
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Fig. 4. Effects of curcumin on cap-dependent and amyloid precursor protein-
internal ribosome entry site (APP-IRES)-mediated translation initiation in
neuroblastoma cells. About 7e8  104 N2A cells were seeded on a 24-well
plate. A DNA plasmid containing IRES elements of the 50UTR amyloid
precursor protein (pGS-APP) was transfected using Turbofect reagent with
centrifugation at 600  g at 26C for 10 min. Cells were allowed to proliferate
and were treated with various concentrations of curcumin (1 mM, 5 mM,
10 mM, 20 mM, and 40 mM). After 24 h, the cell medium was aspirated and
subjected to a secreted alkaline phosphatase (SEAP) activity assay while the
adherent cells were lysed by Cytobuster and lysates were subjected to a b-
galactosidase assay.
559O.B. Villaflores et al. / Taiwanese Journal of Obstetrics & Gynecology 51 (2012) 554e564assay, where curcumin was able to cause an inhibitory effect
on the APP-IRES-mediated translation initiation (Fig. 6A). It
can be seen that upon treating N2A cells with increasing
amounts of curcumin, the level of APP expression is decreased
significantly, whereas treatment of N2A cells with deme-
thoxycurcumin at increasing concentrations resulted in
a promotion of APP expression (Fig. 6B). These data suggest
that curcumin and not demethoxycurcumin may play a role inthe treatment of AD through the modulation of APP-IRES
activity. This is because demethoxycurcumin, at doses
tested, was able to promote APP-IRES activity as seen on the
increased expression of APP in the western blot analysis.
Zhang and colleagues investigated the effect of curcumin on
the metabolism of amyloid-b and APP in various cell lines
including rat neuroblastoma cells overexpressing human
APP751. Curcumin significantly increased the levels of
matured APP at low concentrations (5 mM and 10 mM), and
there was an observed decrease in the level of matured APP at
15 mM and 20 mM. As a result, curcumin treatment markedly
increased the ratio of matured APP and immature APP at
Fig. 6. Effects of (A) curcumin and (B) demethoxycurcumin on APP C-
terminal protein expression. N2A cells (w7e8  104) were seeded on a 24-
well plate, and these were treated with various concentrations of either
curcumin or demethoxycurcumin (1 mM, 5 mM, 10 mM, 20 mM, and 40 mM).
The cell lysates were subjected to western blot analysis. Total protein
concentration was measured using BCA Total Protein Kit (Pierce). Proteins
(40 mg) were resolved by 8% sodium dodecylsulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) followed by electrotransferring onto a poly-
vinylidene fluoride (PVDF) membrane. Detection of APP C-terminal protein
was accomplished by the use of rabbit polyclonal anti-APP, C-terminal
primary antibody (1:2500), and incubation with secondary anti-rabbit HRP
conjugated antibody (1:3000). Bands were visualized using VistaGlow
Chemiluminescent Substrate. Bands were quantified using ImageJ software
and were presented as relative area corresponding to APP expression. Data
presented are results from three independent experiments.
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decreased at higher concentrations of curcumin [29].
Curcumin and demethoxycurcumin are structural analogues
and, because demethoxycurcumin has one methoxy groupfewer than curcumin, it can be deduced that the methoxy
group is important in the curcumin molecule in terms of its
ability to act on the IRES elements of APP. The methoxy
group also gives curcumin a more hydrophobic character,
making it capable of penetrating the plasma membrane more
easily compared to demethoxycurcumin.
On a different note, demethoxycurcumin, as mentioned
above, increased the expression of APP in untransfected
neuroblastoma cells consistent with the SEAP activity data
from the transient transfection of pGS-APP in N2A cells.
However, the addition of demethoxycurcumin to N2A cells did
not substantially affect the b-galactosidase activity, in this
manner the cap-dependent translation within the cell was not
affected by demethoxycurcumin treatment. In connection with
this, the MTT assay result for demethoxycurcumin-treated
N2A cells showed an increased viability with increasing
concentrations of demethoxycurcumin. A previous in vitro
study showed that curcuminoids isolated from Curcuma longa
were able to protect PC12 pheochromocytoma cells and
human umbilical vein endothelial cells from amyloid-b1-42
insults [30]. Considering the structure of curcuminoids, the
protection effect is due to the presence of the 4-hydroxy group
on the cinnamate portion of the compound while the 3-
hydroxy group is less effective in protecting the cells [31].
Based on the presented results and observations, it could be
possible that demethoxycurcumin may play a protective role in
murine neuroblastoma cells.Curcumin and demethoxycurcumin exhibit opposing
effects on tau IRES-mediated translation initiationStudies have shown that curcuminoid compounds are able
to attenuate tau phosphorylation and tau pathologies. Curcu-
min and demethoxycurcumin were tested for their ability to
inhibit the tau IRES-mediated translation initiation in vitro,
using pGS-Tau transfected N2A cells. It is observed in Fig. 7
that curcumin minimally caused an effect on the cap-
dependent translation in N2A cells at concentrations less
than 10 mM based on the b-galactosidase assay. This obser-
vation is consistent with the findings of the MTT assay for
curcumin against N2A cells proving that curcumin is not
cytotoxic to N2A cells at 10 mM and below. However, there
was an observed dose-dependent decrease in the beta-
galactosidase activity at concentrations above 10 mM, that is,
about 20% at 20 mM and 50% at 40 mM curcumin as compared
to the b-galactosidase activity in the untreated cells. Interest-
ingly, curcumin promoted tau-IRES-mediated translation as
seen on the measured SEAP activity in the cell medium of
1 mM, 5 mM, and 10 mM curcumin-treated N2A cells.
Furthermore, a dose-dependent increase in the SEAP activity
was observed at these concentrations. There was significant
reduction in the SEAP activity at 20 mM (70% inhibition) and
40 mM (80% inhibition). However, these concentrations may
have some detrimental effects when used because curcumin
affected the viability as well as the cap-dependent translation
in N2A cells. Demethoxycurcumin enhanced the activity of
SEAP after addition to N2A cells at 1 mM, 5 mM, 10 mM,
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Fig. 7. Effect of curcumin on the cap-dependent and tau internal ribosome
entry site (IRES)-mediated translation initiation in neuroblastoma cells. About
7e8  104 N2A cells were seeded on a 24-well plate. A DNA plasmid con-
taining IRES elements of the 50UTR amyloid precursor protein (pGS-Tau) was
transfected using Turbofect reagent with centrifugation at 600  g at 26C for
10 min. N2A cells were allowed to proliferate and were treated with various
concentrations of curcumin (1 mM, 5 mM, 10 mM, 20 mM, and 40 mM). After
24 hours, the cell medium was aspirated and subjected to a secreted alkaline
phosphatase (SEAP) activity assay while the adherent cells were lysed by
Cytobuster and lysates were subjected to a b-galactosidase assay.
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Fig. 8. Effect of demethoxycurcumin on tau-internal ribosome entry site
(IRES)-dependent translation in murine neuroblastoma cells. About
7e8  104 N2A cells were seeded on a 24-well plate. A DNA plasmid con-
taining IRES elements of the 50UTR amyloid precursor protein (pGS-Tau) was
transfected using Turbofect reagent with centrifugation at 600  g at 26C for
10 min. Cells were allowed to proliferate and were treated with various
concentrations of demethoxycurcumin (1 mM, 5 mM, 10 mM, 20 mM, and
40 mM). After 24 h, the cell medium was aspirated and subjected to a secreted
alkaline phosphatase (SEAP) activity assay while the cells were lysed by
Cytobuster and lysates were subjected to a b-galactosidase assay.
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not observed from the SEAP assay, while the b-galactosidase
assay was in agreement with the MTT assay data for deme-
thoxycurcumin on N2A cells.Effects of curcumin and demethoxycurcumin on the
expression of total tau and phosphorylated tauThe tau protein is a microtubule-associated protein present
in brain and other neuronal tissues. It is expressed predomi-
nantly in axons of both the central and the peripheral nervoussystem, but is barely detectable in astrocytes or oligodendro-
cytes. Total and phosphorylated tau proteins are considered
promising candidate biomarkers for AD. Phosphorylation at
some sites in the tau protein has been reported to play
a dominant role in the reduction of the binding capacity of tau
to the microtubule. Of the 79 potential serine and threonine
phosphorylation sites, 39 have already been verified [32].
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that Serine 262 (pS262) was phosphorylated by CaM kinase II
as well as cAMP-kinase and MAP/microtubule affinity regu-
lating kinase [33]. Furthermore, tau protein in AD brain was
found to be phosphorylated at Serine 396 (pS396) [34]. In this
study, the levels of total tau protein as well as the phosphor-
ylated tau at Serine 262 and Serine 396 were determined after
the treatment of mouse neuroblastoma cells with curcumin and
demethoxycurcumin.Fig. 9. Effect of (A) curcumin and (B) demethoxycurcumin on total tau (human tau
Cells (w7e8  104 cells/well) were treated with various concentrations of curcum
The cell lysates (40 mg protein) were subjected to 8% sodium dodecylsulfate-poly
antibodies against human tau-1 (1:1500), Tau pS262 (1:2500) and Tau pS396 (1:2500)
using VistaGlow Chemiluminescent Substrate kit. The bands were quantified usinBased on Fig. 9A, N2A cells were treated with curcumin at
different doses such as 1 mM, 5 mM, 10 mM, 20 mM, and
40 mM. After 24 hours treatment, the cells were lysed and the
lysates were subjected to western blot analysis. Using ImageJ
software, the levels of the specific tau protein were quantified
as the area of each peak corresponding to the bands visualized
on the PVDF membrane by the enhanced chemiluminescence
detection. Beta-actin was used as internal control to normalize
the level of the tau expression. It was observed that at low-1) and phosphorylated tau pS262 and tau pS396 in murine neuroblastoma cells.
in or demethoxycurcumin (1 mM, 5 mM, 10 mM, 20 mM, and 40 mM) for 24 h.
acrylamide gel electrophoresis (SDS-PAGE) and Western blot analysis using
and secondary anti-rabbit HRP (1:3000). Detection and visualization was done
g ImageJ Software.
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amount of the total tau. However, at concentrations of 20 mM
and 40 mM, the amount of the total tau (hTau-1) was dose-
dependently decreased by 40% and 50%, respectively.
Furthermore, the degree of tau pS262 was decreased markedly
by up to 30% upon treatment of cells with 5e40 mM curcu-
min. The amount of tau pS396, however, was increased
compared to the untreated cells by approximately 20%. It is
noticeable that at 1 mM curcumin both tau pS262 and pS396
were present, although this had very little effect on the hTau-1
level. It is worth noting that at 20 mM and 40 mM curcumin,
the amounts of pS262 and pS396 were almost equivalent.
By correlating the results of the western blot analysis with
those of the MTT assay, it can be deduced that curcumin is
relatively safe for N2A cells at concentrations <10 mM. The
increased viability of N2A at concentrations less than 10 mM
curcumin from the MTT assay may be attributed to the
maintenance of the integrity and stability of the microtubules
inferred from the result obtained from western blot analysis
for total hTau-1. Western blot analysis of cell lysates from the
demethoxycurcumin-treated N2A cells revealed that 1e10 mM
demethoxycurcumin did not elicit any effect of the hTau-1
expression but higher concentrations of demethoxycurcumin
such as 20 mM and 40 mM obviously increased the expression
of hTau-1 in N2A cells (Fig. 9B). Interestingly, it can be
discerned that demethoxycurcumin exhibited a dose-
dependent reduction in the expression of tau pS262 at
10 mM, 20 mM, and 40 mM concentrations while 1 mM and
5 mM demethoxycurcumin marginally increased the expres-
sion of tau pS262. Analysis of the level of expression showed
that demethoxycurcumin was able to diminish the amount of
tau pS396 at all concentrations tested. It is ascertained that the
curcuminoids (curcumin and demethoxycurcumin) may play
a potential role in treatment of AD via the modulation of tau
protein expression and its phosphorylation. Curcumin can act
as a promoter of tau IRES-mediated translation initiation at
concentrations less than 10 mM and may act as inhibitor of the
tau IRES at higher concentration, i.e., 20 mM, without
significantly affecting the cap-dependent translation machin-
eries with the cell. Consistently, curcumin was able to main-
tain the amount of total tau proteins that may account for the
viability of N2A cells at concentrations <10 mM. Although
demethoxycurcumin was not able to inhibit the tau IRES-
dependent translation initiation in murine N2A cells, the
results from the western blot imply that demethoxycurcumin
can prevent AD through its action on the stalling of the
phosphorylation of tau at Serines 262 and 396, apart from the
protective role it gave to the cells.
Conclusion
This study presented the use of a bi-cistronic reporter assay
as a method to determine the effects of curcumin and deme-
thoxycurcumin on AD by the use of IRES elements housed in
a single expression vector. In this bi-cistronic construct, the
IRES element (APP and Tau) is flanked by gene sequences
from b-galactosidase and SEAP. The expression of the b-galactosidase protein was controlled by the cytomegalovirus
promoter, which corresponded to the cap-dependent trans-
lation. The expression of SEAP was under the control of the
IRES element, which represented the cap-independent trans-
lation. Both APP and Tau IRES were functional in the
neuroblastoma cells. Natural compounds used for the study
were observed to be of potential use for the treatment of either
AD or enteroviral infection. Curcumin was more active than
demethoxycurcumin in inhibiting the APP and Tau IRES
activity because demethoxycurcumin failed to inhibit
APPeIRES but was able to reduce Tau activity only at the
highest concentration tested equal to 40 mM. Western blot
analysis further proved the usefulness of the compounds tested
for AD. Curcumin was able to attenuate the expression of APP,
C-terminal protein, tau pS262, and tau pS396 while demethox-
ycurcumin failed to inhibit APP and C-terminal protein. On the
contrary, demethoxycurcumin was able to halt the expression
of tau pS262 and tau pS396. The mechanism to explain the
interactions between the IRES elements and the curcuminoids
needs to be addressed in the future. The bi-cistronic vector
reporter assay provided a novel, simple, and effective platform
in screening and establishing the mechanistic action of poten-
tial compounds for the treatment and management of AD.
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